Lipella Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIPO research report →
About the company
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications.
- CEO
- Jonathan Kaufman
- IPO
- 2022
- Employees
- 5
- HQ
- Pittsburgh, PA, US
Price Chart
- Market Cap
- $600.71K
- P/E
- -0.05
- P/S
- 3.46
- P/B
- 0.40
- EV/EBITDA
- 0.19
- Div Yield
- 0.00%
- Gross Margin
- -1954.73%
- Op Margin
- -3115.15%
- Net Margin
- -3068.97%
- ROE
- -208.44%
- ROIC
- -308.84%
- Revenue
- $536.36K · 19.29%
- Net Income
- $-5,016,264 · -8.60%
- EPS
- $-4.79 · 22.24%
- Op Income
- $-5,080,542
- FCF YoY
- -24.84%
- 52W High
- $0.94
- 52W Low
- $0.02
- 50D MA
- $0.08
- 200D MA
- $0.24
- Beta
- 1.50
- Avg Volume
- 35.70K
Get TickerSpark's AI analysis on LIPO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 3, 25 | Kaufman Jonathan H | other | 536,959 |
| Apr 3, 25 | Kaufman Jonathan H | other | 4,060 |
| Mar 13, 25 | Kaufman Jonathan H | other | 10,326 |
| Mar 13, 25 | Kaufman Jonathan H | other | 4,060 |
| Mar 10, 25 | Kaufman Jonathan H | other | 84,700 |
| Mar 10, 25 | Kaufman Jonathan H | other | 28,924 |
| Feb 28, 25 | Kaufman Jonathan H | other | 441,933 |
| Feb 28, 25 | Kaufman Jonathan H | other | 125,833 |
| Jan 15, 25 | Kaufman Jonathan H | other | 11,795 |
| Jan 15, 25 | Kaufman Jonathan H | other | 303,041 |
Our LIPO coverage
Recent articles, reports, and earnings notes.
No research on LIPO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LIPO report →Similar companies
Peers in the same neighborhood.